NVAX Stock Risk & Deep Value Analysis

Novavax, Inc.

DVR Score

7.8

out of 10

Solid Pick

The Bottom Line on NVAX

We analyzed Novavax, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran NVAX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Oct 1, 2025•Run Fresh Analysis →

📈NVAX Performance Overview3yr weekly

📊

Unlock NVAX Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

NVAX Deep Value Analysis

Novavax offers high-risk, high-reward potential. The transformative Sanofi partnership critically validates its protein platform, providing capital and market access for the promising COVID-Flu combo and RSV vaccines, targeting multi-billion dollar markets. This significantly mitigates prior financial and commercialization risks. While historical execution was mixed, current leadership shows strategic adaptability. Key catalysts are combo vaccine approvals and RSV market penetration. Major risks persist in clinical trial execution and intense competition, but the Sanofi deal provides a credible path to 10x growth, accepting high volatility, away from 'dud' status.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

🔔

Never miss a move on NVAX

Create a free account to set price alerts and get notified on Telegram when NVAX hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Novavax, Inc. (NVAX)?

As of October 1, 2025, Novavax, Inc. has a DVR Score of 7.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

How often is the NVAX DVR analysis updated?

Our AI-powered analysis of Novavax, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on October 1, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.